

PRESS RELEASE April 27, 2010

Resolutions from Biovitrum's AGM

The Biovitrum Annual General Meeting (AGM) convened earlier today in Stockholm and voted in favour of all resolutions proposed at the meeting, including:

The AGM approved the proposal to carry forward the retained profits of SEK 497,914,090.

The AGM discharged the members of the Board and the President from liability for the financial year 2009.

The ordinary board members Hans Glemstedt, Bo Jesper Hansen, Wenche Rolfsen, Michael Steinmetz and Hans Wigzell were re-elected and Adine Grate Axén and Lennart Johansson were elected as new board members. Bo Jesper Hansen was elected chairman of the Board.

Mats-Olof Ljungkvist, Peter Sellei and Håkan Åström had declined re-election. Adine Grate Axén is board member of EDB Business Partners, advisor and executive board member of 3 Scandinavia, member of the commission for the sale of shares in companies with state ownership, as well as chairman of the Listing Committee of Nasdaq OMX Stockholm. Previously she held a number of leading positions within Investor AB. Adine Grate Axén has a Masters degree from Stockholm School of Economics and Harvard AMP. Lennart Johansson is member of the management group and the head of Operating Investments of Investor AB, as well as board member of, among others, Saab AB, Mölnlycke AB and Gambro AB. Previously he was, among other things, managing director of b-business partners and Emerging Technologies AB. Lennart Johansson has a Master degree from Stockholm School of Economics.

The AGM approved the compensation to the Board totaling SEK 1,755,000, of which SEK 250,000 is paid to each of the board members with exception of the chairman who shall not receive any compensation. The AGM further approved that fees for work in the audit committee should be SEK 75,000 to the chairman and SEK 40,000 to each other member of such committee, that no fees should be paid for work in the compensation & benefit committee and that fees for work in the scientific committee should be SEK 50,000 to the chairman and SEK 25,000 to each other member of such committee.

The AGM approved the proposed guidelines for remuneration for the management.

The AGM approved the proposed instructions and charter for the nomination committee.

The AGM decided to adopt the Board's proposal regarding amendments to the articles of association, partly for change of the company name to Swedish Orphan Biovitrum AB (publ), partly for the purpose of clarifying the pre-emptive right which shall be applicable for holders of common shares and C-shares, respectively, in the event of cash or set-off issues.

The AGM approved the Board's proposal on the implementation of a performance based, long-term share program for 2010 ("Share Program 2010"), comprising a resolution regarding amendment of the articles of association, a resolution regarding a directed issue of C-shares and a resolution regarding authorization for the Board to repurchase issued C-shares. The program includes up to 80 managers

and key employees of the Biovitrum-group, which receive the possibility to be allocated common shares in Biovitrum free of charge. An offer to participate in the program shall be provided no later than on 31 December 2010. The participants of the program shall be divided into three categories: members of the management team and two additional categories for other managers and key employees. For each category, the Board will determine a maximum value for the Share Program 2010 related to the participant's salary. The program participants are nominated based on competence and performance as well as taking into consideration the strategic importance of retaining key employees within the business. For each participant, the Board establishes, following a proposal from the compensation & benefit committee, an individual maximum value denominated in SEK. Each maximum value shall thereafter be converted into a maximum number of shares that may be allocated, based on the volume weighted average closing share price of the Biovitrum common share during a period of ten trading days before the day the participants are offered to participate in the program. The outcome of the Share Program 2010 is dependent on the fulfillment of targets for value creation, determined by the Board, connected to the total shareholder return of the Biovitrum common share, during a three year period as from the date of the offer to participate in the program. The participants must purchase common shares in Biovitrum at market value to be allowed to participate in the Share Program 2010 at a value within an amount interval based on their annual base salary. For each common share that a participant purchases, the participant is given the possibility, provided that certain conditions are fulfilled, to receive one common share in Biovitrum free of charge. Based on a number of assumptions, the maximum costs for the Share Program 2010 are calculated to approximately SEK 12.5 million. Additional costs for social security charges are calculated to approximately SEK 4.3 million. Upon full allocation according to Share Program 2010, the number of shares in Biovitrum will be increased with approximately 985,000 corresponding to a dilution effect of approximately 0.5 per cent of the share capital and the votes. To secure that the company can fulfill its commitment according to Share Program 2010 and Share Program 2008 and 2009, the AGM resolved to issue not more than 1,552,949 C-shares to an external party, whereby the company's share capital may be increased with not more than approximately SEK 852,100, and to authorize the Board to repurchase all issued C-shares. In order to enable the share issue the AGM also resolved to amend the articles of association so that the maximum number of C-shares that may be issued is increased from 2,000,000 to 5,000,000.

At the statutory meeting of the Board held in conjunction with the AGM, Lennart Johansson (chairman), Adine Grate Axén and Hans Glemstedt were elected to the audit committee, and Bo Jesper Hansen (chairman), Hans Glemstedt and Michael Steinmetz to the compensation & benefit committee.

For full details on each proposal adopted by the AGM please refer to www.biovitrum.com where documentation related to the AGM can be downloaded.

CEO Martin Nicklasson's address to the meeting is also available www.biovitrum.com.

For more information, contact:

Martin Nicklasson, CEO
Phone: +46 8 697 20 00

Göran Arvidson, CFO
Cell phone: +46 70 633 30 42

Erik Kinnman, VP Investor Relations
Cell phone: +46 73 422 15 40
erik.kinnman@biovitrum.com

About Swedish Orphan Biovitrum

On January 14, 2010, Biovitrum AB (publ) completed the acquisition of Swedish Orphan International Holding AB and created Swedish Orphan Biovitrum - a leading company focused on treatment of rare diseases.

Swedish Orphan Biovitrum is a Swedish based specialty pharmaceutical company with an international market presence. The company is focused on providing and developing orphan and niche specialist pharmaceuticals to patients with high medical needs. The portfolio consists of about 60 marketed products and an emerging late stage clinical development pipeline within rare diseases. Swedish Orphan Biovitrum has pro-forma revenues 2009e of about 2 BSEK and approximately 500 employees. The head office is located in Sweden and the share (STO: BVT) is listed on NASDAQ OMX Stockholm. For more information please visit www.biovitrum.com.

Swedish Orphan Biovitrum may be required to disclose the information provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was provided for public release on April 27, 2010 at 7.30 p.m. CET.